- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | IO Biotech, Inc. (NASDAQ:IOBT) CEO Acquires $10,125.00 in Stock | 3 | MarketBeat | ||
| Fr | IO Biotech announces up to €57.5M debt financing from the European Investment Bank | 2 | Seeking Alpha | ||
| Fr | IO Biotech secures €57.5 million EIB loan for cancer vaccines | 1 | Investing.com | ||
| Fr | IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank | 1 | GlobeNewswire (USA) | ||
| 16.12. | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| IO BIOTECH Aktie jetzt für 0€ handeln | |||||
| 21.11. | IO Biotech stock hits 52-week low at $0.73 amid market challenges | 2 | Investing.com | ||
| 21.11. | IO Biotech-Aktie erreicht 52-Wochen-Tief bei 0,73 US-Dollar | 2 | Investing.com Deutsch | ||
| 12.11. | IO Biotech, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | IO Biotech GAAP EPS of -$0.36 misses by $0.09 | 1 | Seeking Alpha | ||
| 12.11. | IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights | 97 | GlobeNewswire (Europe) | Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced... ► Artikel lesen | |
| 07.11. | Promising results for IO Biotech's cancer vaccine | 1 | Investing.com | ||
| 07.11. | IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic ... | 72 | GlobeNewswire (Europe) | -- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response... ► Artikel lesen | |
| 04.10. | IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 16.09. | Piper Sandler hält an Overweight-Einstufung für IO Biotech fest | 7 | Investing.com Deutsch | ||
| 16.09. | Piper Sandler maintains Overweight rating on IO Biotech shares | 1 | Investing.com | ||
| 14.09. | IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer | 518 | GlobeNewswire (Europe) | -- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals... ► Artikel lesen | |
| 09.09. | Morgan Stanley maintains Overweight rating on IO Biotech shares | 6 | Investing.com | ||
| 03.09. | Piper Sandler maintains Overweight rating on IO Biotech shares | 3 | Investing.com | ||
| 03.09. | IO Biotech shares hold as trial continues, Buy rating affirmed | 2 | Investing.com | ||
| 31.08. | IO Biotech's Phase 3 Trial Data Fails To Show Superiority In ORR For IO102-IO103 With KEYTRUDA | 779 | AFX News | KENILWORTH (NJ) (dpa-AFX) - IO Biotech (IOBT) announced that the Independent Data Monitoring Committee found the data from the Pivotal Phase 3 Trial of IO102-IO103 in combination with KEYTRUDA... ► Artikel lesen |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,402 | -0,99 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,950 | -1,65 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,270 | +4,01 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,740 | +0,14 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| ARCTURUS THERAPEUTICS | 16,340 | -1,03 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,881 | +4,18 % | Assertio Holdings, Inc.: Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study | LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,390 | -1,86 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,980 | +0,67 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,430 | +1,23 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,300 | -1,81 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,785 | -1,95 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,940 | +1,45 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,030 | -7,21 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
Das Unternehmen IO BIOTECH INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IO BIOTECH INC finden Sie auf Wallstreet Online.
